Request Information


Media coverage of Auris Health

Contact us

FDA-cleared Monarch Platform Featured in Xconomy

Operated by a hand-held controller, Auris Health’s recently FDA-cleared Monarch Platform has lung cancer as its first targeted disease state. According to the article, the FDA determined the technology Auris built was equivalent to other bronchoscopic procedures that use endoscopy to examine a patient’s lungs. However, with the integration of the latest advancements in robotics, software, data science, and endoscope innovation, Auris aims to go further than conventional endoscopy.

Continue Reading

Auris Gets FDA Clearance for Monarch Platform

Auris Health's Monarch Platform has been cleared by the FDA. The company's Chief Strategy Officer, Josh DeFonzo, summarizes some of the key features and benefits of the new technology, aimed to improve the current bronchoscopy procedure.

Continue Reading

Monarch Platform's Clearance Featured in Fierce BioTech

Fred Moll’s Auris Health has been granted FDA clearance for its surgical robotics platform. The nod clears the Intuitive Surgical founder’s latest venture to sell the device for use in bronchoscopic diagnostic and therapeutic procedures in lung cancer patients.

Continue Reading

What Medtech Companies Raised the Most VC Last Year?

Auris Health, formerly known as Auris Surgical Robotics, made its way to the top for most venture capital funding in the medical device industry in 2017, marking an exciting time not only for Auris but for the industry overall last year.

Continue Reading

Auris Receives High Valuation

Auris Health, formerly known as Auris Surgical Robotics, finds itself in good company with other billion-dollar valuation startups, all working to revolutionize healthcare in 2018.

Continue Reading

Auris's Monarch Platform featured in The Economist

Even when Auris Health, Inc., formerly known as Auris Surgical Robotics, was in stealth mode, it was featured as one of the new surgical robots about to enter the surgical suites. Dr. Fred Moll, CEO of Auris, is a well known as a pioneer in medical robotics. When Dr. Moll began developing the Monarch Platform, there was much speculation about his work. Lung cancer was identified as a key disease state that Auris was going to tackle.

Continue Reading

Dr. Michael Machuzak Interviewed on Auris's Technology

In this video interview at CHEST's Annual Meeting, Dr. Machuzak of the Cleveland Clinic summarizes his experience using the Monarch Platform in Auris's study, REACH Assessment: Advanced Bronchoscopic Techniques. According to Machuzak, Auris's robotic bronchoscope was compared to other standard flexible bronchoscopes, and the results were encouraging.

Continue Reading

Secretive Surgical Robotics Company Raises $280 Million

Auris Health, formerly known as Auris Surgical Robotics, is featured in the article for raising an unprecedented amount of funding in 2017. According to this article, Auris raised $280 million in a Series D round. After raising a large investment, Auris has remained silent about its work on the Monarch Platform, creating great intrigue in the financial media.

Continue Reading

Auris Technology for Less Invasive Procedures

Auris Health, formerly known as Auris Surgical Robotics, is featured in this article for its significant achievement in financing along with details surrounding its technology. Under the leadership of serial entrepreneur and Auris CEO, Dr. Fred Moll, Auris raised $280 million in a Series D round of financing. This was a generous amount to add to the existing $149.5 million from its Series C financing.

Continue Reading

Auris in TechCrunch

Auris is featured in this TechCrunch article not only for its impressive Series D funding but also for the opportunity it brings with its focus on the lung cancer market. Lung cancer claims more victims than prostate, breast, and colon cancer combined. It remains a very dangerous form of cancer because a diagnosis often comes late, when the cancer has already spread.

Continue Reading